ArticleBMC cardiovascular disorders2026
Clinical prognostic value of cartilage intermediate layer protein 1 (CILP-1) in elderly patients with acute myocardial infarction.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the levels of human cartilage intermediate layer protein 1 (CILP-1) in elderly patients with acute myocardial infarction (AMI), its correlation with myocardial ischemia and ventricular remodeling, and its prognostic value for major adverse cardiovascular events (MACE).
methodsA total of 1869 elderly patients admitted to the Second Affiliated Hospital of Soochow University for chest pain within 24 h of onset were enrolled. Participants were categorized into the AMI group (n = 849) and the non-AMI group (n = 1020). The plasma CILP-1 levels were measured upon admission. In the AMI group, the wall motion score (WMS) was recorded within 24 h of pain onset, and the SYNTAX score was evaluated based on coronary angiography. Statistical analysis of MACE occurrence during 12-month follow-up was performed in the AMI patients.
resultsCILP-1 levels were significantly higher in the AMI group compared to the non-AMI group (1058.33 [793.73, 1397.05] ng/L vs. 975.60 [700.24, 1279.41] ng/L, P < 0.05), and notably higher in the MACE group than in the non-MACE group (1650.3 [1074.61, 1718.04] ng/L vs. 976.40 [738.00, 1287.78] ng/L, P < 0.05). CILP-1 expression correlated positively with WMS, SYNTAX score, myocardial injury markers, C-reactive protein (CRP), and left-ventricular end-diastolic diameter (LVDd), and negatively with left-ventricular ejection fraction (LVEF) (P < 0.05). Univariate Cox analysis indicated that CILP-1, age, cardiac troponin T (cTn-T), creatine kinase-MB (CK-MB), myoglobin, CRP, LVEF, WMS, and SYNTAX were significant predictors of MACE in AMI patients (P < 0.05). After adjusting for confounding factors, CK-MB, LVEF, WMS, and SYNTAX remained independent predictors of MACE (P < 0.05). Furthermore, incorporating CILP-1 into a baseline model (comprising LVEF, male sex, SYNTAX, WMS, CRP, and CK-MB) significantly enhanced risk estimation for MACE (AUC 0.78, 95% CI:0.75–0.80 vs. AUC 0.59, 95% CI:0.55–0.62; P < 0.05).
conclusionsElderly AMI patients present significantly elevated CILP-1 levels, which positively correlate with the degree of ischemia and ventricular remodeling. CILP-1 may serve as a potential prognostic biomarker for risk stratification in elderly AMI patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.